Plasma 25-hydroxyvitamin D3 is associated with decreased risk of postmenopausal breast cancer in whites: a nested case–control study in the multiethnic cohort study

BMC Cancer

Yeonju Kim¹  Adrian A Franke⁴  Yurii B Shvetsov¹  Lynne R Wilkens¹  Robert V Cooney⁵  Galina Lurie¹  Gertraud Maskarinec¹  Brenda Y Hernandez¹  Loïc Le Marchand¹  Brian E Henderson³  Laurence N Kolonel¹  Marc T Goodman² 

[1] Cancer Epidemiology Program, University of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, HI 96813, USA

[2] Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Room 1S37, Los Angeles, CA 90048, USA

[3] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 1450 Biggy Street, NRT 1517 J, Los Angeles, CA 90033, USA

[4] Cancer Biology Program, University of Hawaii Cancer Center, 1236 Lauhala Street, Honolulu, HI 96813, USA

[5] Department of Public Health Sciences & Epidemiology, University of Hawaii, 1960 East West Road, Biomed D104K, Honolulu, HI 96822, USA

关键词: Nested case–control study;    Ethnic groups;    25-Hydroxyvitamin D2;    25-Hydroxyvitamin D3;    Breast cancer;   

Others  :  859129
DOI  :  10.1186/1471-2407-14-29

 received in 2013-09-03, accepted in 2014-01-14,  发布年份 2014

【 摘 要 】

Background

Higher sunlight exposure is correlated with lower incidence of breast cancer in ecological studies, but findings from prospective studies regarding the association of circulating levels of vitamin D with the risk of breast cancer have been null. The objective of this study was to examine the relation between plasma levels of vitamin D and the risk of postmenopausal breast cancer.

Methods

We conducted a nested case–control study within the Multiethnic Cohort Study of five race/ethnic groups (white, African-American, Native Hawaiian, Japanese, and Latino) from Hawaii and Los Angeles between 2001 and 2006. Pre-diagnostic plasma levels of 25-hydroxyvitamin D2 [25(OH)D₂], 25-hydroxyvitamin D3 [25(OH)D₃] and 25(OH)D (sum of 25(OH)D₂ and 25(OH)D₃) were examined among 707 postmenopausal breast cancer cases and matched controls.

Results

Using conditional logistic regression models, 20 ng/mL increases of plasma 25(OH)D₃ (odds ratio (OR) 0.28; 95% confidence interval (CI) 0.14-0.56) and 25(OH)D (OR 0.43; 95% CI 0.23-0.80) were inversely associated with breast cancer risk among white women, but not among women in other race/ethnic groups. Using two-segmented, piecewise-linear logistic regression models, the change-points of the ORs, either for 25(OH)D₃ or for 25(OH)D, were detected as 20 ng/mL among whites.

Conclusions

Circulating 25(OH)D₃ and 25(OH)D were associated with a reduced risk of postmenopausal breast cancer among whites, but not in other ethnic groups, who reside in low latitude regions.

【 授权许可】

   
2014 Kim et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Boscoe FP, Schymura MJ: Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993–2002. BMC Cancer 2006, 6:264. BioMed Central Full Text
• [2]Gorham ED, Garland FC, Garland CF: Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 1990, 19(4):820-824.
• [3]Grant WB: An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94(6):1867-1875.
• [4]IARC: Vitamin D and cancer. IARC Working group reports vol.5. Volume 5. Lyon: International Agency for research on Cancer; 2008.
• [5]Gissel T, Rejnmark L, Mosekilde L, Vestergaard P: Intake of vitamin D and risk of breast cancer—a meta-analysis. J Steroid Biochem Mol Biol 2008, 111(3–5):195-199.
• [6]Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, Lipkin M, Newmark H, Holick MF, Garland FC: Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 2007, 103(3–5):708-711.
• [7]Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, Autier P: Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011, 128(6):1414-1424.
• [8]Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H: Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer 2010, 46(12):2196-2205.
• [9]Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J: Serum levels of vitamin D, PTH and calcium and breast cancer risk-a prospective nested case–control study. Int J Cancer 2010, 127(9):2159-2168.
• [10]Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE: Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Bioiomarkers Prev 2005, 14(8):1991-1997.
• [11]Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE: Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II. Breast Cancer Res 2011, 13(3):R50. BioMed Central Full Text
• [12]Engel P, Fagherazzi G, Boutten A, Dupre T, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F: Serum 25(OH) vitamin D and risk of breast cancer: a nested case–control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 2010, 19(9):2341-2350.
• [13]Freedman DM, Chang S-C, Falk RT, Purdue MP, Huang W-Y, McCarty CA, Hollis BW, Graubard BI, Berg CD, Ziegler RG: Serum levels of Vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2008, 17(4):889-894.
• [14]McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL, Gapstur SM, Thun MJ, Calle EE: Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res 2009, 11(4):R64. BioMed Central Full Text
• [15]Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, Heickendorff L, Mosekilde L: Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case–control study. Cancer Epidemiol Biomarkers Prev 2009, 18(10):2655-2660.
• [16]Scarmo S, Afanasyeva Y, Lenner P, Koenig K, Horst R, Clendenen T, Arslan A, Chen Y, Hallmans G, Lundin E, et al.: Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: a nested case–control study. Breast Cancer Res 2013, 15(1):R15. BioMed Central Full Text
• [17]Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O’Sullivan MJ, Yasmeen S, et al.: Calcium plus Vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 2008, 100(22):1581-1591.
• [18]Neuhouser ML, Manson JE, Millen A, Pettinger M, Margolis K, Jacobs ET, Shikany JM, Vitolins M, Adams-Campbell L, Liu S, et al.: The influence of health and lifestyle characteristics on the relation of serum 25-hydroxyvitamin D with risk of colorectal and breast cancer in postmenopausal women. Am J Epidemiol 2012, 175(7):673-684.
• [19]Ford L, Graham V, Wall A, Berg J: Vitamin D concentrations in an UK inner-city multicultural outpatient population. Ann Clin Biochem 2006, 43(Pt 6):468-473.
• [20]Holick M: Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr 1995, 61(3):638S-645S.
• [21]Nessvi S, Johansson L, Jopson J, Stewart A, Reeder A, McKenzie R, Scragg RK: Association of 25-hydroxyvitamin D3)levels in adult New Zealanders with ethnicity, skin color and self-reported skin sensitivity to sun exposure. Photochem Photobiol 2011, 87(5):1173-1178.
• [22]Ashwell M, Stone EM, Stolte H, Cashman KD, Macdonald H, Lanham-New S, Hiom S, Webb A, Fraser D: UK Food Standards Agency Workshop Report: an investigation of the relative contributions of diet and sunlight to vitamin D status. Br J Nutr 2010, 104(4):603-611.
• [23]Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA: Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2000–2004. Am J Clin Nutr 2008, 88(6):1519-1527.
• [24]IOM (Institue of Medicine): Dietary reference intakes for calcium and vitamin D. Washington, D.C: The National Academy Press; 2011.
• [25]Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, et al.: IOM Committee Members Respond to Endocrine Society Vitamin D Guideline. J Clin Endocrinol Metab 2012, 97(4):1146-1152.
• [26]Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM: Evaluation, treatment, and prevention of Vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011, 96(7):1911-1930.
• [27]Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, Stram DO, Monroe KR, Earle ME, Nagamine FS: A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000, 151(4):346-357.
• [28]Pastor R, Guallar E: Use of two-segmented logistic regression to estimate change-points in epidemiologic studies. Am J Epidemiol 1998, 148(7):631-642.
• [29]Manson JE, Mayne ST, Clinton SK: Vitamin D and prevention of cancer–ready for prime time? N Engl J Med 2011, 364(15):1385-1387.
• [30]Nicholas J: Vitamin D and cancer: uncertainty persists; research continues. J Natl Cancer Inst 2011, 103(11):851-852.
• [31]Zerwekh JE: Blood biomarkers of vitamin D status. Am J Clin Nutr 2008, 87(4):1087S-1091S.
• [32]Engel P, Fagherazzi G, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F: Joint effects of dietary vitamin D and sun exposure on breast cancer risk: results from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 2011, 20(1):187-198.
• [33]John EM, Schwartz GG, Dreon DM, Koo J: Vitamin D and breast cancer risk: The NHANES I epidemiologic follow-up study, 1971–1975 to 1992. Cancer Epidemiol Biomarkers Prev 1999, 8(5):399-406.
• [34]Bolland MJ, Grey A, Gamble GD, Reid IR: Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. Am J Clin Nutr 2011, 94(4):1144-1149.
• [35]Chai W, Maskarinec G, Cooney RV: Serum 25-hydroxyvitamin D levels and mammographic density among premenopausal women in a multiethnic population. Eur J Clin Nutr 2010, 64(6):652-654.
• [36]Kuroda T, Shiraki M, Tanaka S, Ohta H: Contributions of 25-hydroxyvitamin D, co-morbidities and bone mass to mortality in Japanese postmenopausal women. Bone 2009, 44(1):168-172.
• [37]Millen AE, Wactawski-Wende J, Pettinger M, Melamed ML, Tylavsky FA, Liu S, Robbins J, LaCroix AZ, LeBoff MS, Jackson RD: Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: the Women's Health Initiative Calcium plus Vitamin D clinical trial. Am J Clin Nutr 2010, 91(5):1324-1335.
• [38]Ohta H, Kuroda T, Onoe Y, Orito S, Ohara M, Kume M, Harada A, Tsugawa N, Okano T, Sasaki S: The impact of lifestyle factors on serum 25-hydroxyvitamin D levels: a cross-sectional study in Japanese women aged 19–25 years. J Bone Miner Metab 2009, 27(6):682-688.
• [39]Anderson LN, Cotterchio M, Cole DE, Knight JA: Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev 2011, 20(8):1708-1717.
• [40]Ingles SA, Garcia DG, Wang W, Nieters A, Henderson BE, Kolonel LN, Haile RW, Coetzee GA: Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Control 2000, 11(1):25-30.
• [41]McKay JD, McCullough ML, Ziegler RG, Kraft P, Saltzman BS, Riboli E, Barricarte A, Berg CD, Bergland G, Bingham S, et al.: Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev 2009, 18(1):297-305.
• [42]Rollison DE, Cole AL, Tung KH, Slattery ML, Baumgartner KB, Byers T, Wolff RK, Giuliano AR: Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U.S. Breast Cancer Res Treat 2011, 132(2):683-691.
• [43]Trabert B, Malone KE, Daling JR, Doody DR, Bernstein L, Ursin G, Marchbanks PA, Strom BL, Humphrey MC, Ostrander EA: Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case–control study of Caucasian and African-American women. Breast Cancer Res 2007, 9(6):R84. BioMed Central Full Text
• [44]Khan QJ, Kimler BF, Fabian CJ: The relationship between vitamin D and breast cancer incidence and natural history. Curr Oncol Rep 2010, 12(2):136-142.
• [45]John EM, Schwartz GG, Koo J, Wang W, Ingles SA: Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. Am J Epidemiol 2007, 166(12):1409-1419.
• [46]Li B, Byrjalsen I, Glendenning P, Henriksen DB, Hoeck HC, Taranto M, Vasikaran S, Fraser WD, Christiansen C, Qvist P: Selective monitoring of vitamin D2 and D3 supplementation with a highly specific 25-hydroxyvitamin D3 immunoassay with negligible cross-reactivity to 25-hydroxyvitamin D2. Clin Chim Acta 2009, 404(2):144-148.
• [47]Heaney RP, Recker RR, Grote J, Horst RL, Armas LA: Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab 2011, 96(3):E447-452.
• [48]Houghton LA, Vieth R: The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 2006, 84(4):694-697.
• [49]Chlebowski RT: Vitamin D and breast cancer: interpreting current evidence. Breast Cancer Res 2011, 13(4):217. BioMed Central Full Text